Author of

• 18972

  +

  P2.02 - Biology/Pathology (ID 616)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Biology/Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23268

    +

    P2.02-070 - C-MET as a Biomarker in Patients with Surgically Resected Non-Small Cell Lung Cancer (ID 10323)

    09:30 - 09:30  |  Author(s): S. Ekman
    • Abstract
    • Slides

    Background:
    c-MET protein overexpression has been proposed as potential prognostic as well as predictive biomarker for targeted therapy in non-small cell lung cancer (NSCLC), albeit its role in the clinical setting has not been firmly established yet and no clear cut-off value exists for immunohistochemistry (IHC) score.
    
    Method:
    We designed a retrospective cohort study, consisting of 725 patients with surgically removed non-small cell lung cancer. IHC was conducted in tissue microarrays (TMA) from lung tumors and healthy tissue adjacent to the tumor, using a specific antibody against human c-MET (MET PharmDx). IHC staining was quantified using H-scores (range 0-300). Association between c-MET H-score and overall survival (OS) as well as progression-free survival (PFS) was explored.
    
    Result:
    c-MET H-score over 20 had a significant protective impact on OS in the multivariate analysis in the whole study population, both as continuous variable (p=0.014), as well as dichotomous variable with HR=0.79 (95%CI: 0.64-0.97, p-value = 0.022). The prognostic effect of c-MET H-score over 20 was stronger in patients who received adjuvant treatment with a HR=0.61 (95% CI: 0.40-0.93, p-value=0.022). In the subgroup of adenocarcinoma and squamous cell carcinoma patients with stage IIA-IIIB disease, the prognostic impact of c-MET was significant even in the univariate analysis (HR=0.60, 95% CI: 0.43-0.83, p-value=0.002).
    
    Conclusion:
    c-MET H score > 20 is a positive prognostic biomarker for OS in early stage NSCLC. This benefit seems to be strongly correlated to adjuvant chemotherapy, therefore rendering c-MET H-score > 20 a possible predictive biomarker for platinum-based adjuvant chemotherapy in early stage NSCLC.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.